Louis Ates | Senior Scientist - Infectious Disease Vaccines
BioNTech

Louis Ates is the preclinical lead of tuberculosis vaccine development at BioNTech (Mainz, Germany). This includes (pre/non-clinical) portfolio management of BNT164a1 and BNT164b1 candidates, which are currently in clinical trials. His main role is to shape research and development to translate the latest insights in TB immunology and the mRNA platform into innovations to improve mRNA-based TB vaccine development. Before joining BionTech in 2022, Louis obtained his PhD and held two Post-Doctoral positions studying different aspects of tuberculosis and other pathogenic Mycobacteria, with a particular focus on secreted bacterial proteins and how these influence the virulence, pathogenicity, immunogenicity and evolution of these important pathogens.